Article
Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.
Chinese clinical oncology - 1 Jun 2017
Han Catherine H, Batchelor Tracy T
Abstract excerpt
Isocitrate dehydrogenases (IDH) are important enzymes that catalyze the oxidative decarboxylation of isocitrate to α-ketoglutarate (α-KG), producing NADPH in the process. More than 80% of low-grade gliomas and secondary glioblastoma (GBM) harbor an IDH mutation. IDH mutations involve the catalytic pocket of the enzyme and lead to a neomorphic ability to produce 2-hydroxyglutarate (2HG) while oxidizing NADPH to...
Topics
Join the communities discussing this publication.